Medgenics Inc

Type: Company
Name: Medgenics Inc
First reported Sep 24 2014 - Updated Sep 24 2014 - 2 reports

Medgenics to Announce Third Quarter 2014 Results and Provide Initial Clinical Data on MDGN-201 (EPODURE(TM)) Trial on October 15, 2014

WAYNE, Pa. and MISGAV, Israel, Sept. 24, 2014 (GLOBE NEWSWIRE) -- .Details on the conference call and webcast will be made available one week prior to the call.About Medgenics, Inc.Medgenics is developing an autologous transduced micro-organ system, BioPump™, ... [Published Wall Street Select - Sep 24 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

TransCelerate BioPharma Inc. Publishes Risk-Based Monitoring Recommendations for Central Monitoring and Technology Considerations

TransCelerate's RBM methodology is based on the notion that shifting monitoring processes from an excessive concentration on Source Data Verification (SDV) to comprehensive, risk-driven monitoring that uses a combination of Central, Off-site and On-site ... [Published Industrial Info Financials - Sep 17 2014]
First reported Sep 16 2014 - Updated Sep 17 2014 - 1 reports

SAGE Therapeutics Appoints Michael F. Cola to the Company's Board of Directors

CAMBRIDGE, Mass., Sept. 16, 2014 (GLOBE NEWSWIRE) -- (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced the appointment of Michael ... [Published EMoneyDaily - Sep 16 2014]
First reported Sep 11 2014 - Updated Sep 11 2014 - 1 reports

Enanta Reports Initiation of ABT-493 Phase 2B; Nymox Announces Positive Prostate Cancer Trial Results

Below is a look at some of the headlines for companies that made news in the healthcare sector on September 10, 2014.Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focusedbiotechnology company dedicated to creating small molecule ... [Published BioMedReports - Sep 11 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 2 reports

Medgenics Announces the Appointment of Scott Applebaum as Chief Legal Officer

WAYNE, Pa. and MISGAV, Israel, Sept. 10, 2014 (GLOBE NEWSWIRE) -- ."We are very excited to have Scott join our management team. He has a demonstrated ability to lead teams through the necessary operational, legal, strategic and regulatory hurdles associated ... [Published EMoneyDaily - Sep 10 2014]
First reported Sep 08 2014 - Updated Sep 09 2014 - 1 reports

Renal Anemia - Pipeline Review, H2 2014 - 22 Companies & 25 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/3xpp5q/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic ... [Published Individual.com - Sep 08 2014]
First reported Sep 02 2014 - Updated Sep 03 2014 - 2 reports

TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports

SOURCE TransCelerate BioPharma Inc.PHILADELPHIA, Sept. 2, 2014 /PRNewswire/ -- TransCelerate BioPharma Inc. ("TransCelerate") today announced that it has developed a recommended approach for protecting personal data in Clinical Study Reports (CSRs) that ... [Published 3 WRCB-TV - Sep 02 2014]

Quotes

...m. EDT to discuss third quarter 2014 financial and operational results and to provide initial clinical data from the ongoing MDGN-201 trial, "Safety and Efficacy of Sustained Erythropoietin Therapy of Anemia in Chronic Kidney Disease Patients and End-Stage Renal Disease (ESRD) Dialysis Patients Using EPODURE BioPump."
"As the TransCelerate RBM initiative has outlined, successful implementation of risk-based monitoring is dependent on being able to operationalize the concepts effectively through multiple considerations, including process, people, and technology. Risk assessment, central monitoring and technology to scale the methodology are all important for success" said Brett Wilson
"It's an honor to join SAGE Therapeutics at such an important time," said Mr. Cola. "With a successful IPO and the rapid development of its lead compound, SAGE-547, the company is poised to deliver new treatments for patients suffering from CNS disorders with few or no treatment options. I look forward to partnering with the SAGE team to expand and develop these efforts."
"We are very excited to have Scott join our management team. He has a demonstrated ability to lead teams through the necessary operational, legal, strategic and regulatory hurdles associated with drug development and commercialization. We greatly look forward to his insight and guidance during this important time of growth as we formalize our development strategy going forward" commented Michael Cola, President and Chief Executive Officer of Medgenics

More Content

All (10) | News (10) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Medgenics to Announce Third Quarter 2014 Result... [Published Wall Street Select - Sep 24 2014]
Medgenics to Announce Third Quarter 2014 Result... [Published CW 50 Detroit - Sep 24 2014]
TransCelerate BioPharma Inc. Publishes Risk-Bas... [Published Industrial Info Financials - Sep 17 2014]
SAGE Therapeutics Appoints Michael F. Cola to t... [Published EMoneyDaily - Sep 16 2014]
Enanta Reports Initiation of ABT-493 Phase 2B; ... [Published BioMedReports - Sep 11 2014]
Medgenics Announces the Appointment of Scott Ap... [Published EMoneyDaily - Sep 10 2014]
Medgenics Announces the Appointment of Scott Ap... [Published CBS Detroit - Sep 10 2014]
Renal Anemia - Pipeline Review, H2 2014 - 22 Co... [Published Individual.com - Sep 08 2014]
TransCelerate BioPharma Inc. Releases Recommend... [Published 3 WRCB-TV - Sep 02 2014]
TransCelerate BioPharma Inc. Releases Recommend... [Published Minyanville - Sep 02 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.